Abstract |
Inhalation of neurokinin A (NKA) causes bronchoconstriction in patients with asthma. In vitro both tachykinin NK1 and NK2 receptors can mediate airway contraction. In this study the authors examined the effects of a single dose of the dual tachykinin NK1/NK2 receptor antagonist, DNK333, on NKA-induced bronchoconstriction in asthma. A total of 19 male adults with mild asthma completed a randomised, double-blind, placebo-controlled crossover trial. Increasing concentrations of NKA (3.3x10(-9) to 1.0x10(-6) mol x mLP(-1)) were inhaled at 1 and 10 h intervals after a single oral dosing with either DNK333 (100 mg) or a placebo. It was observed that DNK333 did not affect baseline lung function but did protect against NKA-induced bronchoconstriction in those patients. The mean log10 provocative concentration causing a 20% fall in forced expiratory volume in one second for NKA was -5.6 log10 mol x mL(-1) at 1 h after DNK333 treatment and -6.8 log10 mol x mL(-1) after placebo. This was equivalent to a difference of 4.08 doubling doses, which decreased to a difference of 0.90 doubling doses 10 h after treatment. The results shown in this report indicate that DNK333 blocks neurokinin A-induced bronchoconstriction in patients with asthma.
|
Authors | G F Joos, W Vincken, R Louis, V J Schelfhout, J H Wang, M J Shaw, G D Cioppa, R A Pauwels |
Journal | The European respiratory journal
(Eur Respir J)
Vol. 23
Issue 1
Pg. 76-81
(Jan 2004)
ISSN: 0903-1936 [Print] England |
PMID | 14738235
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aza Compounds
- Benzamides
- DNK 333
- Receptors, Tachykinin
- Neurokinin A
|
Topics |
- Administration, Inhalation
- Adolescent
- Adult
- Asthma
(physiopathology)
- Aza Compounds
(administration & dosage, pharmacokinetics, pharmacology)
- Benzamides
(administration & dosage, pharmacokinetics, pharmacology)
- Bronchoconstriction
(drug effects)
- Cross-Over Studies
- Double-Blind Method
- Humans
- Middle Aged
- Neurokinin A
(administration & dosage, adverse effects)
- Receptors, Tachykinin
(antagonists & inhibitors)
|